Biofrontera Inc. To Participate In The Lytham Partners Spring 2026 Investor Conference On May 28, 2026

(MENAFN- GlobeNewsWire - Nasdaq) WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the“Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

Company Webcast

The webcast presentation will take place at 11:00 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at or directly at . The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at ... or register for the event at .

About Biofrontera Inc.

Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz^® with the RhodoLED^® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers¹. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate-to-severe acne. For more information, visit and follow Biofrontera on LinkedIn and X.

Investor Relations

Ben Shamsian
646-829-9701
...

MENAFN21052026004107003653ID1111150627